Oculis Holding AG (OCS) FY 2025 Conference May 20, 2025 09:30 AM ET Speaker0 For this session, we'll have a presentation by Oculus. Oculus is a clinical stage ophthalmology company with a pipeline of candidates targeting diabetic macular edema, dry eye disease and acute optic neuritis. Presenting for the company is Ms. Silva Chin, Chief Financial Officer of Oculus. Speaker1 Thank you. Good morning, everyone. Thank you for your patience, and thank you, Yi, for the introduction. Thanks to H. C. Ringwright for ...

Summary of Oculis Holding AG (OCS) Conference Call Company Overview - Oculis Holding AG is a global biopharmaceutical company focused on innovations in ophthalmology and neuro-ophthalmology [3][4] - The company is dual listed and has three core assets with multiple indications [3] Financial Position - Oculis reported $206 million in cash and cash equivalents as of March, with no debt and a runway extending into early 2028 [4] Core Assets and Indications 1. **OCS01 (OptiReach)** - A proprietary eye drop formulation of high concentration dexamethasone targeting diabetic macular edema (DME) [5][6] - Addresses a large unmet medical need with less than 60% of patients diagnosed and only 44% treated [9][10] - Estimated total US addressable patient population is 1.3 million [12] - Positive results from phase three studies, with a letter gain of 7.2 at week six and 7.6 at week twelve [13] - Safety profile is favorable with no unexpected adverse events [14] 2. **OCS05 (Preval Sector)** - A neuroprotective peptide small molecule targeting acute optic neuritis [6][18] - Demonstrated a 43% improvement in retinal ganglion cell thickness and 30% improvement in axon health at month six [25] - The indication has orphan drug designation and no approved therapies currently exist [20][33] 3. **OCS02 (Likaminomap)** - A topical anti-TNF eye drop for dry eye disease, utilizing a genotype-based precision medicine approach [34][35] - Only 13% of patients currently experience lasting relief from existing treatments [35] - Phase two study showed significant efficacy, particularly in patients with the TNF R1 genotype [38] Market Opportunity - The DME market is large and growing, with significant unmet needs due to low patient compliance with current invasive treatments [9][12] - The company aims to position OCS01 as a first-line treatment for early intervention and as a combination therapy for patients not responding adequately to existing treatments [12][17] - The total diagnosed population for DME is approximately 1.8 million, with a significant portion untreated [48] Commercial Strategy - Initial promotional efforts will focus on retinal specialists who treat patients with anti-VEGF therapies, followed by general ophthalmologists [50][51] - The company plans to leverage the existing patient base and the need for non-invasive treatment options [50][52] Future Milestones - Phase three results for OCS01 are expected in Q2 of the following year, with an NDA submission anticipated in the second half of 2026 [16][18] - Discussions with the FDA regarding registrational studies for OCS05 and OCS02 are planned for the second half of the year [33][34] Conclusion - Oculis is positioned to transform its product portfolio from ophthalmology to neuro-ophthalmology, with multiple late-stage assets and a strong clinical profile [42][43] - The company is focused on advancing its lead candidates and addressing significant unmet medical needs in the ophthalmology market [44]

Oculis Holding AG (OCS) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.44 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50.98%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.76, delivering a surprise of -58.33%.Over the last four quarters, the company has not b ...

[Unaudited Condensed Consolidated Interim Financial Statements](index=2&type=section&id=Unaudited%20Condensed%20Consolidated%20Interim%20Financial%20Statements) This section presents the unaudited condensed consolidated interim financial statements, detailing the company's financial performance and position [Statements of Financial Position](index=3&type=section&id=Statements%20of%20Financial%20Position) Total assets significantly increased to **CHF 204.2 million** by March 31, 2025, driven by higher current assets, leading to a substantial rise in total equity due to share issuances Condensed Statement of Financial Position (in CHF thousands) | | As of March 31, 2025 | As of December 31, 2024 | | :--- | :--- | :--- | | **Total Assets** | **204,171** | **120,353** | | Total non-current assets | 15,382 | 15,456 | | Total current assets | 188,789 | 104,897 | | *Cash and cash equivalents* | *59,873* | *27,708* | | *Short-term financial assets* | *122,055* | *70,955* | | **Total Equity and Liabilities** | **204,171** | **120,353** | | **Total Equity** | **162,626** | **73,383** | | Total Liabilities | 41,545 | 46,970 | [Statements of Loss](index=4&type=section&id=Statements%20of%20Loss) The company reported a net loss of **CHF 33.2 million** for Q1 2025, significantly wider than the prior year, primarily due to increased operating expenses and a substantial negative finance result Statement of Loss Highlights (in CHF thousands) | | For the three months ended March 31, 2025 | For the three months ended March 31, 2024 | | :--- | :--- | :--- | | Operating income | 285 | 222 | | Research and development expenses | (14,771) | (10,856) | | General and administrative expenses | (5,488) | (4,694) | | **Operating loss** | **(19,974)** | **(15,328)** | | Fair value adjustment on warrant liabilities | (11,911) | (3,069) | | **Loss for the period** | **(33,213)** | **(16,093)** | | **Basic and diluted loss per share** | **(0.69)** | **(0.44)** | [Statements of Comprehensive Loss](index=5&type=section&id=Statements%20of%20Comprehensive%20Loss) Total comprehensive loss for Q1 2025 was **CHF 32.7 million**, significantly higher than the prior year, primarily driven by the net loss for the period Comprehensive Loss Reconciliation (in CHF thousands) | | For the three months ended March 31, 2025 | For the three months ended March 31, 2024 | | :--- | :--- | :--- | | Loss for the period | (33,213) | (16,093) | | Other comprehensive (loss) income | 548 | 31 | | **Total comprehensive loss for the period** | **(32,665)** | **(16,062)** | [Statements of Changes in Equity](index=6&type=section&id=Statements%20of%20Changes%20in%20Equity) Total equity more than doubled to **CHF 162.6 million** in Q1 2025, primarily driven by significant inflows from share issuances and warrant exercises, partially offset by the net loss Key Changes in Equity - Q1 2025 (in CHF thousands) | Item | Amount | | :--- | :--- | | Balance as of January 1, 2025 | 73,383 | | Issuance of ordinary shares | 90,227 | | Warrants exercised | 35,719 | | Loss for the period | (33,213) | | Share-based compensation expense | 2,630 | | Transaction costs | (6,982) | | **Balance as of March 31, 2025** | **162,626** | [Statements of Cash Flows](index=7&type=section&id=Statements%20of%20Cash%20Flows) Despite increased operating and investing cash outflows, strong financing activities led to a net increase in cash and cash equivalents of **CHF 33.4 million** for Q1 2025 Summary of Cash Flows (in CHF thousands) | | For the three months ended March 31, 2025 | For the three months ended March 31, 2024 | | :--- | :--- | :--- | | Net cash outflow for operating activities | (18,963) | (13,720) | | Net cash outflow for investing activities | (51,505) | (1,512) | | Net cash inflow from financing activities | 103,831 | 171 | | **(Decrease) increase in cash and cash equivalents** | **33,363** | **(15,061)** | - Effective January 1, 2025, the company reclassified **interest paid** from operating to financing activities and **interest received** from operating to investing activities, with prior periods recast for comparability[18](index=18&type=chunk)[22](index=22&type=chunk) [Notes to the Unaudited Condensed Consolidated Interim Financial Statements](index=8&type=section&id=Notes%20to%20the%20Unaudited%20Condensed%20Consolidated%20Interim%20Financial%20Statements) This section provides detailed explanations supporting the financial statements, covering corporate information, accounting policies, financing activities, and specific breakdowns of assets, liabilities, and equity [1. Corporate Information](index=8&type=section&id=1.%20Corporate%20Information) Oculis Holding AG is a Swiss-based, global late clinical-stage biopharmaceutical company focused on developing innovative treatments for ophthalmic and neuro-ophthalmic diseases - Oculis is a global **late clinical-stage biopharmaceutical company** focused on therapeutics for ophthalmic and neuro-ophthalmic diseases[15](index=15&type=chunk) - The company's mission is to improve patient health by developing medicines that **save sight and improve eye care**[15](index=15&type=chunk) [2. Basis of Preparation and Changes to the Group's Accounting Policies](index=8&type=section&id=2.%20Basis%20of%20Preparation%20and%20Changes%20to%20the%20Group%27s%20Accounting%20Policies) The financial statements are prepared on a going concern basis, with a key accounting policy change reclassifying interest paid and received on the cash flow statement, applied retrospectively - The Board believes the Group has **sufficient funds for at least the next 12 months**, supported by current cash and February 2025 offering proceeds[16](index=16&type=chunk) - The company's long-term viability depends on its ability to **raise additional capital** to finance future operations[17](index=17&type=chunk) - Effective January 1, 2025, **interest paid and received were reclassified** on the cash flow statement from operating to financing and investing activities, respectively, applied retrospectively[18](index=18&type=chunk)[22](index=22&type=chunk) [3. Summary of Material Accounting Policies, Critical Judgments and Accounting Estimates](index=10&type=section&id=3.%20Summary%20of%20Material%20Accounting%20Policies%2C%20Critical%20Judgments%20and%20Accounting%20Estimates) Accounting policies and estimates remain consistent with 2024 annual statements, while the company evaluates the potential impact of **IFRS 18**, effective January 1, 2027 - Critical accounting estimates, assumptions, and judgments are **unchanged** from the 2024 annual financial statements[27](index=27&type=chunk) - The company is assessing the impact of **IFRS 18**, a new presentation and disclosure standard effective for periods beginning on or after January 1, 2027[29](index=29&type=chunk) [4. Financing Activities](index=12&type=section&id=4.%20Financing%20Activities) Key financing activities included a **CHF 90.2 million** share offering, establishment of a **CHF 50.0 million** loan facility, and a **$100.0 million** ATM offering program - In February 2025, the company raised **gross proceeds of CHF 90.2 million ($100.0 million)** from an underwritten offering of **5,000,000 ordinary shares**[30](index=30&type=chunk) - A loan facility agreement with Kreos Capital provides up to **CHF 50.0 million** in borrowing capacity, with no amounts drawn as of March 31, 2025[31](index=31&type=chunk) - An **ATM offering program** was established to sell up to **$100.0 million** of ordinary shares, with no sales through March 31, 2025[34](index=34&type=chunk) [5. Segment Information](index=14&type=section&id=5.%20Segment%20Information) Oculis operates as a **single business segment**, with the majority of non-current assets, including all intangible assets, located in Switzerland - The company is managed and operated as **one reportable business segment**[37](index=37&type=chunk) Non-Current Assets by Geography (in CHF thousands) | Asset Type | Switzerland | Iceland | Others | Total | | :--- | :--- | :--- | :--- | :--- | | Intangible assets | 13,292 | - | - | 13,292 | | Property and equipment | 188 | 160 | 16 | 364 | | Right-of-use assets | 660 | 558 | - | 1,218 | | **Total** | **14,140** | **718** | **16** | **14,874** | [6. Intangible Assets](index=14&type=section&id=6.%20Intangible%20Assets) Intangible assets totaled **CHF 13.3 million** as of March 31, 2025, primarily comprising licenses for drug candidates Licaminlimab and Privosegtor, with recent milestone payments for the latter - Intangible assets of **CHF 13.3 million** comprise licenses for **Licaminlimab (OCS-02)** from Novartis and **Privosegtor (OCS-05)** from Accure[39](index=39&type=chunk) - Milestone payments of **CHF 1.1 million** to Accure for Privosegtor (OCS-05) were triggered by Phase 2 trial completion and FDA IND clearance, paid in Q1 2025[39](index=39&type=chunk) [7. Income and Expenses](index=14&type=section&id=7.%20Income%20and%20Expenses) Operating expenses increased to **CHF 20.3 million** in Q1 2025, mainly due to higher R&D costs, while the finance result worsened to a **CHF 13.2 million loss** from fair value adjustments and foreign exchange losses Operating Expenses Breakdown (in CHF thousands) | Expense Category | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Research and development | 14,771 | 10,856 | | General and administrative | 5,488 | 4,694 | | **Total operating expenses** | **20,259** | **15,550** | - The increase in R&D spending primarily supported clinical trial expenses for the **Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01** in diabetic macular edema (DME)[41](index=41&type=chunk) Finance Result Breakdown (in CHF thousands) | Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Finance income | 493 | 581 | | Finance expense | (247) | (41) | | Fair value adjustment on warrant liabilities | (11,911) | (3,069) | | Foreign currency exchange gain (loss) | (1,567) | 1,794 | | **Finance result** | **(13,232)** | **(735)** | [8. Other Current Assets and Accrued Income](index=16&type=section&id=8.%20Other%20Current%20Assets%20and%20Accrued%20Income) Other current assets remained stable at **CHF 5.9 million**, with a decrease in prepaid clinical expenses offset by an increase in prepaid G&A expenses and accrued R&D income - The decrease in prepaid clinical expenses resulted from the **advancement of the OCS-01 DIAMOND trials** in DME[44](index=44&type=chunk) - Accrued income is derived from **R&D tax credits** provided by the Icelandic government[45](index=45&type=chunk) [9. Share-based Compensation](index=16&type=section&id=9.%20Share-based%20Compensation) Share-based compensation expense more than doubled to **CHF 2.6 million** in Q1 2025 due to new grants and the vesting of earnout options and shares upon achieving stock price targets - Total share-based compensation expense was **CHF 2.6 million** for Q1 2025, a significant increase from **CHF 1.1 million** in Q1 2024[54](index=54&type=chunk) Share-Based Award Activity - Q1 2025 | Award Type | Granted | Outstanding as of Mar 31, 2025 | | :--- | :--- | :--- | | Options & SARs | 973,931 | 5,217,801 | | Restricted Stock Units (RSUs) | 594,524 | 1,057,287 | - VWAP price targets of **$15.00 and $20.00** were met, resulting in **168,571 earnout options** becoming exercisable[55](index=55&type=chunk) [10. Cash and Cash Equivalents, and Short-term Financial Assets](index=20&type=section&id=10.%20Cash%20and%20Cash%20Equivalents%2C%20and%20Short-term%20Financial%20Assets) The company's liquidity significantly strengthened, with combined cash and short-term financial assets increasing to **CHF 181.9 million**, primarily held in Swiss Francs and US Dollars Cash and Short-Term Financial Assets by Currency (in CHF thousands) | Currency | As of March 31, 2025 | As of December 31, 2024 | | :--- | :--- | :--- | | Swiss Franc | 116,831 | 63,810 | | US Dollar | 56,732 | 25,189 | | Euro | 8,213 | 8,960 | | Other | 152 | 704 | | **Total** | **181,928** | **98,663** | [11. Warrant Liabilities](index=20&type=section&id=11.%20Warrant%20Liabilities) Warrant liabilities decreased to **CHF 14.9 million** in Q1 2025, driven by warrant exercises generating **CHF 18.9 million** in cash, partially offset by a **CHF 11.9 million** fair value loss Warrant Liability Movement - Q1 2025 (in CHF thousands) | Item | Amount | | :--- | :--- | | Balance as of January 1, 2025 | 19,851 | | Fair value loss on warrant liabilities | 11,911 | | Exercise of public and private warrants | (16,825) | | **Balance as of March 31, 2025** | **14,937** | - The exercise of **1,806,297 warrants** in Q1 2025 generated **cash proceeds of CHF 18.9 million**[62](index=62&type=chunk) - The **CHF 11.9 million fair value loss** was primarily due to an increase in the trading price of public warrants[61](index=61&type=chunk) [12. Accrued Expenses and Other Payables](index=22&type=section&id=12.%20Accrued%20Expenses%20and%20Other%20Payables) Accrued expenses and other payables increased to **CHF 19.9 million**, primarily due to higher product development and G&A expenses, partially offset by lower personnel-related costs Accrued Expenses Breakdown (in CHF thousands) | Category | As of March 31, 2025 | As of December 31, 2024 | | :--- | :--- | :--- | | Product development related expenses | 15,354 | 13,702 | | Personnel related expenses | 2,199 | 3,696 | | General and administration related expenses | 2,249 | 749 | | **Total** | **19,860** | **18,198** | [13. Shareholders' Equity](index=22&type=section&id=13.%20Shareholders%27%20Equity) This section details the company's equity structure, including conditional capital, a capital band authorizing up to **22.7 million** new shares, and the vesting of **2.8 million** earnout shares upon achieving stock price targets - The company has a capital band authorizing the Board to issue up to **22,721,850 ordinary shares** until May 29, 2029[71](index=71&type=chunk) - As of March 31, 2025, **3,500,000 treasury shares** were held, reserved for the ATM Offering Program[72](index=72&type=chunk)[9](index=9&type=chunk) - Achieving **$15.00 and $20.00 VWAP targets** resulted in the vesting of **1,422,723 earnout shares** on each occasion[74](index=74&type=chunk) [14. Loss per Share](index=24&type=section&id=14.%20Loss%20per%20Share) Basic and diluted loss per share increased to **CHF 0.69** for Q1 2025, calculated on a net loss of **CHF 33.2 million** and a weighted-average of **48.3 million shares** Loss Per Share Calculation | | For the three months ended March 31, 2025 | For the three months ended March 31, 2024 | | :--- | :--- | :--- | | Net loss (in CHF thousands) | (33,213) | (16,093) | | Weighted-average shares | 48,263,134 | 36,621,162 | | **Basic and diluted net loss per share** | **(0.69)** | **(0.44)** | - **9,435,724 potentially dilutive securities** were excluded from diluted loss per share calculation as their effect was anti-dilutive due to the net loss[78](index=78&type=chunk) [15. Related Party Disclosures](index=26&type=section&id=15.%20Related%20Party%20Disclosures) Key management personnel compensation totaled **CHF 3.4 million** for Q1 2025, a significant increase from the prior year, driven by higher salaries, cash, and share-based compensation Key Management Compensation (in CHF thousands) | Category | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Salaries, cash compensation & other benefits | 1,755 | 966 | | Pension | 105 | 92 | | Share-based compensation expense | 1,522 | 915 | | **Total** | **3,382** | **1,973** | [16. Subsequent Events](index=26&type=section&id=16.%20Subsequent%20Events) No material events occurred after March 31, 2025, that would require disclosure or adjustment in the financial statements - There are **no material subsequent events** to report[81](index=81&type=chunk)

Core Insights - Oculis Holding AG reported significant advancements in its clinical portfolio, including the completion of patient randomization in Phase 3 trials and the initiation of a genotype-based development program in ophthalmology [2][5][6] - The company is well-positioned for future growth with a strengthened financial position and several upcoming value inflection points [2][5] Clinical Developments - OCS-01: Enrollment in Phase 3 DIAMOND trials for diabetic macular edema (DME) has been completed with over 800 patients, with topline results expected in Q2 2026 [5][10] - Licaminlimab (OCS-02): A genotype-based development plan for dry eye disease (DED) is aligned with FDA, with the first registrational trial anticipated in 2H 2025 [5][10] - Privosegtor (OCS-05): Positive results from the ACUITY trial indicate neuroprotective effects, leading to plans for a global registration program in acute optic neuritis and potential expansion into other neuro-ophthalmology indications [5][6][10] Financial Overview - As of March 31, 2025, Oculis reported cash, cash equivalents, and short-term investments totaling $206.3 million, reflecting a significant increase from $109.0 million as of December 31, 2024, due to a $100.0 million financing [5][10] - Research and development expenses for Q1 2025 were $16.4 million, up from $12.4 million in Q1 2024, primarily due to costs associated with active clinical trials [10][14] - The net loss for Q1 2025 was $36.9 million, compared to $18.4 million in the same period in 2024, driven by advancements in clinical development and increased general and administrative expenses [10][14]

Core Insights - Oculis Holding AG reported significant advancements in its clinical portfolio, including the completion of patient randomization in Phase 3 trials and the initiation of a genotype-based development program in ophthalmology [2][5][6] - The company is well-positioned for future growth with a strengthened financial position and several upcoming value inflection points [2][5] Clinical Developments - Oculis completed randomization of over 800 patients in the Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01, with topline results expected in Q2 2026 [5][7] - Licaminlimab (OCS-02) is set to initiate its first registrational trial in the second half of 2025, focusing on a personalized medicine approach for dry eye disease [5][12] - Privosegtor (OCS-05) demonstrated promising neuroprotective effects in the ACUITY trial for acute optic neuritis, with plans for a global registration program [5][6][12] Financial Overview - As of March 31, 2025, Oculis reported cash, cash equivalents, and short-term investments totaling $206.3 million, bolstered by a $100 million financing in February 2025 [5][12] - Research and development expenses for Q1 2025 were $16.4 million, an increase from $12.4 million in Q1 2024, primarily due to active clinical trials [12][16] - The net loss for Q1 2025 was $36.9 million, compared to $18.4 million in the same period in 2024, driven by clinical development advancements and increased general and administrative expenses [12][16] Market Opportunity - Diabetic macular edema (DME) currently affects approximately 37 million people globally, representing a market opportunity of around $5 billion [6]

Company Overview - Oculis Holding AG (OCS) is expected to report a year-over-year decline in earnings with a projected loss of $0.51 per share, reflecting a change of -15.9% compared to the previous year [3] - Revenues are anticipated to remain flat at $0.22 million, unchanged from the year-ago quarter [3] Earnings Expectations - The consensus EPS estimate has been revised 5.01% higher in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Oculis is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -7.32%, suggesting a bearish outlook on earnings prospects [10][11] Historical Performance - Oculis has not been able to beat consensus EPS estimates in any of the last four quarters, with the last reported quarter showing a surprise of -58.33% [12][13] Market Reaction - The stock may experience upward movement if the actual results exceed expectations, while a miss could lead to a decline [2] - The combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict an earnings beat for Oculis [11][16]

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [4] Upcoming Conferences - Oculis will present at several investor conferences, including Bio€quity Europe from May 12-14, 2025, where CEO Riad Sherif will provide a company update on May 14 at 11am CET [1] - The company will also participate in the Bank of America Healthcare Conference from May 13-15, 2025, with CFO Sylvia Cheung engaging in a fireside chat on May 14 at 3pm PT [2] - Additional presentations include the H.C. Wainwright Annual BioConnect at Nasdaq on May 20, 2025, and the Stifel Virtual Ophthalmology Forum on May 27, 2025, both featuring updates from CFO Sylvia Cheung [2] Company Pipeline - Oculis has a differentiated pipeline of innovative product candidates, including OCS-01 for diabetic macular edema, Privosegtor (OCS-05) for acute optic neuritis, and Licaminlimab (OCS-02) for dry eye disease [4]

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [5] Upcoming Conferences - Oculis will present at several investor conferences, including Bio€quity Europe from May 12-14, 2025, where CEO Riad Sherif will provide a company update on May 14 at 11am CET [1] - The company will also participate in the Bank of America Healthcare Conference from May 13-15, 2025, featuring a fireside chat with CFO Sylvia Cheung on May 14 at 3pm PT [2] - Additional presentations include the H.C. Wainwright Annual BioConnect at Nasdaq on May 20, 2025, and the Stifel Virtual Ophthalmology Forum on May 27, 2025, both featuring updates from CFO Sylvia Cheung [2] Company Pipeline - Oculis has a differentiated pipeline that includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis; and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) [5]

Core Insights - Oculis Holding AG is presenting its innovative late-stage pipeline at major ophthalmology conferences, including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress [1][2][3] Pipeline Developments - The DME AWARE Delphi Study interim results will focus on unmet needs in diabetic macular edema (DME) patient management, with insights from the Phase 3 DIAMOND program on OCS-01 eye drops [2][7] - OCS-01 is being developed as the first non-invasive treatment for DME, addressing the need for earlier intervention and for patients who do not respond adequately to current treatments [2][13] - Licaminlimab (OCS-02) is being investigated for dry eye disease (DED) and has shown positive results in Phase 2 trials, with a genetic biomarker identified to predict patient response [3][16] Conference Presentations - Oculis will showcase its developments at the following events: - Eyecelerator 2025 on May 2, 2025, featuring TKI and Drug Delivery [4] - ARVO Annual Meeting on May 5, 2025, presenting interim results of the DME AWARE Delphi Study [7] - Retina World Congress on May 8, 2025, discussing Licaminlimab in DED treatment [7] Market Context - DME currently affects approximately 37 million people globally, with projections to rise to 53 million by 2040 due to increasing diabetes prevalence [15] - DED impacts over 110 million people in G7 countries, with a significant portion of patients remaining unsatisfied with current treatment options [18][19] Company Overview - Oculis is a biopharmaceutical company focused on addressing significant unmet medical needs in ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for DME and Licaminlimab for DED [20]